| Evergreen Speech And Hearing Clinic, Inc | |
|
8301 161st Ave Ne, #203, Redmond, WA 98052-3858 | |
| (425) 882-4347 | |
| (425) 883-0043 |
| Full Name | Evergreen Speech And Hearing Clinic, Inc |
|---|---|
| Type | Facility |
| Speciality | Audiologist |
| Location | 8301 161st Ave Ne, Redmond, Washington |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013934918 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Primary |
| Provider Name | Cheryl L Lokanis |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1598793853 PECOS PAC ID: 5294758637 Enrollment ID: I20060111000737 |
News Archive
Bayer's public takeover offer for Schering AG has been completed. Following expiration of the additional acceptance period, Bayer now has control of 92.4 percent of the approximately 191 million outstanding Schering shares.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.
Improved air quality in cities resulting from cutting carbon emissions could lead to large reductions in childhood asthma cases, premature births and incidences of babies born at an unhealthily low weight, according to a study carried out by researchers at the London School of Hygiene & Tropical Medicine.
U-Systems, the leader in automated breast ultrasound, today announced that the U.S. Food and Drug Administration's Radiological Devices Panel of the Medical Devices Advisory Committee recommended approval of the somo•v Automated Breast Ultrasound (ABUS) system.
› Verified 8 days ago
| Provider Name | Terence A Limb |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1275565459 PECOS PAC ID: 1850389123 Enrollment ID: I20120228000394 |
News Archive
Bayer's public takeover offer for Schering AG has been completed. Following expiration of the additional acceptance period, Bayer now has control of 92.4 percent of the approximately 191 million outstanding Schering shares.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.
Improved air quality in cities resulting from cutting carbon emissions could lead to large reductions in childhood asthma cases, premature births and incidences of babies born at an unhealthily low weight, according to a study carried out by researchers at the London School of Hygiene & Tropical Medicine.
U-Systems, the leader in automated breast ultrasound, today announced that the U.S. Food and Drug Administration's Radiological Devices Panel of the Medical Devices Advisory Committee recommended approval of the somo•v Automated Breast Ultrasound (ABUS) system.
› Verified 8 days ago
| Provider Name | Thomas J Norwood |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1821013871 PECOS PAC ID: 3870589120 Enrollment ID: I20120319000383 |
News Archive
Bayer's public takeover offer for Schering AG has been completed. Following expiration of the additional acceptance period, Bayer now has control of 92.4 percent of the approximately 191 million outstanding Schering shares.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.
Improved air quality in cities resulting from cutting carbon emissions could lead to large reductions in childhood asthma cases, premature births and incidences of babies born at an unhealthily low weight, according to a study carried out by researchers at the London School of Hygiene & Tropical Medicine.
U-Systems, the leader in automated breast ultrasound, today announced that the U.S. Food and Drug Administration's Radiological Devices Panel of the Medical Devices Advisory Committee recommended approval of the somo•v Automated Breast Ultrasound (ABUS) system.
› Verified 8 days ago
| Provider Name | Brianne T Salzmann |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1164975280 PECOS PAC ID: 5597017376 Enrollment ID: I20181004003024 |
News Archive
Bayer's public takeover offer for Schering AG has been completed. Following expiration of the additional acceptance period, Bayer now has control of 92.4 percent of the approximately 191 million outstanding Schering shares.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.
Improved air quality in cities resulting from cutting carbon emissions could lead to large reductions in childhood asthma cases, premature births and incidences of babies born at an unhealthily low weight, according to a study carried out by researchers at the London School of Hygiene & Tropical Medicine.
U-Systems, the leader in automated breast ultrasound, today announced that the U.S. Food and Drug Administration's Radiological Devices Panel of the Medical Devices Advisory Committee recommended approval of the somo•v Automated Breast Ultrasound (ABUS) system.
› Verified 8 days ago
| Provider Name | Christopher T Norwood |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1437775343 PECOS PAC ID: 0446638936 Enrollment ID: I20220613002132 |
News Archive
Bayer's public takeover offer for Schering AG has been completed. Following expiration of the additional acceptance period, Bayer now has control of 92.4 percent of the approximately 191 million outstanding Schering shares.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.
Improved air quality in cities resulting from cutting carbon emissions could lead to large reductions in childhood asthma cases, premature births and incidences of babies born at an unhealthily low weight, according to a study carried out by researchers at the London School of Hygiene & Tropical Medicine.
U-Systems, the leader in automated breast ultrasound, today announced that the U.S. Food and Drug Administration's Radiological Devices Panel of the Medical Devices Advisory Committee recommended approval of the somo•v Automated Breast Ultrasound (ABUS) system.
› Verified 8 days ago
| Provider Name | Nathan F Danneker |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1235757220 PECOS PAC ID: 5092131896 Enrollment ID: I20220614000616 |
News Archive
Bayer's public takeover offer for Schering AG has been completed. Following expiration of the additional acceptance period, Bayer now has control of 92.4 percent of the approximately 191 million outstanding Schering shares.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.
Improved air quality in cities resulting from cutting carbon emissions could lead to large reductions in childhood asthma cases, premature births and incidences of babies born at an unhealthily low weight, according to a study carried out by researchers at the London School of Hygiene & Tropical Medicine.
U-Systems, the leader in automated breast ultrasound, today announced that the U.S. Food and Drug Administration's Radiological Devices Panel of the Medical Devices Advisory Committee recommended approval of the somo•v Automated Breast Ultrasound (ABUS) system.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Evergreen Speech And Hearing Clinic, Inc 8301 161st Ave Ne, #203, Redmond, WA 98052-3858 Ph: (425) 882-4347 | Evergreen Speech And Hearing Clinic, Inc 8301 161st Ave Ne, #203, Redmond, WA 98052-3858 Ph: (425) 882-4347 |
News Archive
Bayer's public takeover offer for Schering AG has been completed. Following expiration of the additional acceptance period, Bayer now has control of 92.4 percent of the approximately 191 million outstanding Schering shares.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.
Improved air quality in cities resulting from cutting carbon emissions could lead to large reductions in childhood asthma cases, premature births and incidences of babies born at an unhealthily low weight, according to a study carried out by researchers at the London School of Hygiene & Tropical Medicine.
U-Systems, the leader in automated breast ultrasound, today announced that the U.S. Food and Drug Administration's Radiological Devices Panel of the Medical Devices Advisory Committee recommended approval of the somo•v Automated Breast Ultrasound (ABUS) system.
› Verified 8 days ago
Carolyn M Anderson, Audiologist Medicare: Not Enrolled in Medicare Practice Location: 15446 Bel Red Rd, Redmond, WA 98052 Phone: 425-883-5320 | |
Janie Marie Rodesiler, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 8301 161st Ave Ne Ste 208, Redmond, WA 98052 Phone: 425-882-4347 | |
Terence Limb, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 8301 161st Ave Ne, Suite 203, Redmond, WA 98052 Phone: 425-260-2135 | |
Cornelia John, Audiologist Medicare: Not Enrolled in Medicare Practice Location: 8301 161st Ave Ne Ste 208, Redmond, WA 98052 Phone: 425-882-4347 | |
Christopher Thomas Norwood, Audiologist Medicare: Accepting Medicare Assignments Practice Location: 8301 161st Ave Ne Ste 208, Redmond, WA 98052 Phone: 425-882-4347 | |
Lindsey Melvin, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 8301 161st Ave Ne Ste 203, Redmond, WA 98052 Phone: 425-882-4347 Fax: 425-883-0043 |